Header Logo

Connection

CHRISTIE BALLANTYNE to Dose-Response Relationship, Drug

Back to Details
This is a "connection" page, showing publications CHRISTIE BALLANTYNE has written about Dose-Response Relationship, Drug.
CHRISTIE BALLANTYNE
Connection Strength
1.680
Dose-Response Relationship, Drug
  1. Effect of Targeting ApoC-III With Plozasiran on Lipoprotein Particle Size and?Number?in?Hypertriglyceridemia. J Am Coll Cardiol. 2025 May 20; 85(19):1839-1854.
    View in: PubMed
    Score: 0.175
  2. Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial. JAMA Cardiol. 2024 Jul 01; 9(7):620-630.
    View in: PubMed
    Score: 0.167
  3. Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia. N Engl J Med. 2024 09 12; 391(10):899-912.
    View in: PubMed
    Score: 0.166
  4. Association Between Omega-3 Fatty Acid Treatment and Atrial Fibrillation in Cardiovascular Outcome Trials: A Systematic Review and Meta-Analysis. Cardiovasc Drugs Ther. 2021 08; 35(4):793-800.
    View in: PubMed
    Score: 0.135
  5. A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. Am J Cardiol. 2017 Aug 15; 120(4):569-576.
    View in: PubMed
    Score: 0.101
  6. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am J Cardiol. 2015 May 01; 115(9):1212-21.
    View in: PubMed
    Score: 0.087
  7. Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial). Am J Cardiol. 2013 Feb 15; 111(4):506-9.
    View in: PubMed
    Score: 0.075
  8. Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study. Am Heart J. 2012 Mar; 163(3):515-21, 521.e1-3.
    View in: PubMed
    Score: 0.071
  9. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol. 2008 May 15; 101(10):1428-36.
    View in: PubMed
    Score: 0.055
  10. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol. 2008 Mar 01; 101(5):625-30.
    View in: PubMed
    Score: 0.053
  11. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol. 2007 Mar 01; 99(5):673-80.
    View in: PubMed
    Score: 0.050
  12. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. Am Heart J. 2006 May; 151(5):975.e1-9.
    View in: PubMed
    Score: 0.047
  13. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol. 2004 Jun 15; 93(12):1487-94.
    View in: PubMed
    Score: 0.042
  14. Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia. N Engl J Med. 2024 09 12; 391(10):913-925.
    View in: PubMed
    Score: 0.041
  15. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003 Mar 10; 163(5):553-64.
    View in: PubMed
    Score: 0.038
  16. Associations of High-Sensitivity Troponin and Natriuretic Peptide Levels With Outcomes After Intensive Blood Pressure Lowering: Findings From the SPRINT Randomized Clinical Trial. JAMA Cardiol. 2021 12 01; 6(12):1397-1405.
    View in: PubMed
    Score: 0.035
  17. Efficacy and safety of an extended-release formulation of fluvastatin for once-daily treatment of primary hypercholesterolemia. Am J Cardiol. 2000 Oct 01; 86(7):759-63.
    View in: PubMed
    Score: 0.032
  18. Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System. Cardiovasc Drugs Ther. 2021 06; 35(3):533-538.
    View in: PubMed
    Score: 0.032
  19. Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides. Postgrad Med. 2019 Aug; 131(6):390-396.
    View in: PubMed
    Score: 0.030
  20. Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study). Am J Cardiol. 2019 09 01; 124(5):696-701.
    View in: PubMed
    Score: 0.029
  21. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017 09 21; 377(12):1119-1131.
    View in: PubMed
    Score: 0.026
  22. Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial. Clin Cardiol. 2017 Mar; 40(3):138-148.
    View in: PubMed
    Score: 0.025
  23. On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). Am Heart J. 2016 Dec; 182:89-96.
    View in: PubMed
    Score: 0.024
  24. Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies. Prostaglandins Other Lipid Mediat. 2016 09; 125:57-64.
    View in: PubMed
    Score: 0.024
  25. Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: insights from Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin. Arterioscler Thromb Vasc Biol. 2014 Nov; 34(11):2465-72.
    View in: PubMed
    Score: 0.021
  26. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet. 2011 Oct 29; 378(9802):1547-59.
    View in: PubMed
    Score: 0.017
  27. Peripheral artery disease, biomarkers, and darapladib. Am Heart J. 2011 May; 161(5):972-8.
    View in: PubMed
    Score: 0.017
  28. Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial. J Am Coll Cardiol. 2011 Mar 01; 57(9):1111-9.
    View in: PubMed
    Score: 0.016
  29. Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy. Am J Cardiol. 2010 May 15; 105(10):1409-12.
    View in: PubMed
    Score: 0.016
  30. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). Am J Cardiol. 2009 Jun 15; 103(12):1694-702.
    View in: PubMed
    Score: 0.015
  31. Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome. Clin Ther. 2003 Jun; 25(6):1670-86.
    View in: PubMed
    Score: 0.010
  32. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol. 2003 Jan 01; 91(1):33-41.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.